CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica, Inc. (NASDAQ:CALC) shares are down on Wednesday after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial.The trial was evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). Data was expected in the first half of 2026.The stock is trading lower with a session volume of 23.27 million, compared to the average volume of 84.063 thousand.CalciMedica Halts KOURAGE Trial Due to Safety Conc ...